Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 25, 2023
Product Development
Another sickle cell program stumbles. This time a small molecule
Clinical hold for Fulcrum’s FTX-6058 follows trio of gene therapy setbacks
BioCentury | Oct 3, 2020
Translation in Brief
A SARS-CoV-2 genome degrader; neutralizing influenza B mAbs; Fulcrum’s sickle cell therapy increases fetal hemoglobin and more
BioCentury’s roundup of translational news
BioCentury | Mar 10, 2017
Targets & Mechanisms
Poly drugs for polycomb
Novartis and Abbvie throw a third strike to Polycomb.
BioCentury | Jun 23, 2016
Distillery Techniques
Techniques: Structural analyses of polycomb repressive complex 2 (PRC2) bound to an inhibitor and a mutant histone H3 substrate
BioCentury | May 19, 2016
Tools & Techniques
The long view
Why lncRNA pioneer Jeannie Lee thinks the field is ripe for investment
BioCentury | Apr 14, 2016
Product R&D
Clearing the RaNAway
How RaNA is raising RNA levels with two different platforms
Items per page:
1 - 10 of 22